Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

OCX

Oncocyte Corporation

Dec 13 • 11:23AM ET

2.33

Dollar change -0.06
Percentage change -2.51	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: EXAS CDNA GH FLGT ILMN MYGN BNTX RCKT CRSP TXG

| Held by: VTI VXF IWC DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.43	Insider Own	17.04%	Shs Outstand	16.84M	Perf Week	-4.89%
Market Cap	39.23M	Forward P/E	-	EPS next Y	-1.67	Insider Trans	91.27%	Shs Float	13.97M	Perf Month	-20.74%
Income	-43.61M	PEG	-	EPS next Q	-0.43	Inst Own	51.24%	Short Float	1.57%	Perf Quarter	-26.03%
Sales	0.71M	P/S	55.26	EPS this Y	25.60%	Inst Trans	-	Short Ratio	3.38	Perf Half Y	-14.65%
Book/sh	0.73	P/B	3.21	EPS next Y	40.02%	ROA	-56.84%	Short Interest	0.22M	Perf Year	-11.06%
Cash/sh	0.20	P/C	11.68	EPS next 5Y	-	ROE	-165.32%	52W Range	1.98 - 3.82	Perf YTD	-6.80%
Dividend Est.	-	P/FCF	-	EPS past 5Y	14.72%	ROI	-351.16%	52W High	-39.00%	Beta	0.91
Dividend TTM	-	Quick Ratio	0.47	Sales past 5Y	16.25%	Gross Margin	-166.22%	52W Low	17.68%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	0.49	EPS Y/Y TTM	66.17%	Oper. Margin	-3227.36%	RSI (14)	34.56	Volatility	5.43% 8.65%
Employees	46	Debt/Eq	0.41	Sales Y/Y TTM	-	Profit Margin	-6150.92%	Recom	2.33	Target Price	4.12
Option/Short	No / Yes	LT Debt/Eq	0.28	EPS Q/Q	-21.47%	Payout	-	Rel Volume	0.44	Prev Close	2.39
Sales Surprise	-35.50%	EPS Surprise	7.99%	Sales Q/Q	-73.19%	Earnings	Nov 12 AMC	Avg Volume	64.92K	Price	2.33
SMA20	-6.85%	SMA50	-17.07%	SMA200	-19.82%	Trades		Volume	9,261	Change	-2.51%

Date	Action	Analyst	Rating Change	Price Target Change
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight	$3.10
Jan-06-22	Resumed	Piper Sandler	Overweight	$3.10
Mar-17-21	Resumed	Needham	Buy	$8
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy	$6
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $4
Nov-30-20	Initiated	BTIG Research	Buy	$5
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$5
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy	$7 → $6
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral	$2
Jun-02-20	Initiated	Needham	Buy	$4
Feb-13-19	Initiated	Piper Jaffray	Overweight	$6
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

Show Previous Ratings

Dec-09-24 04:05PM	Oncocyte to Participate in J.P. Morgan Week and Host Investor Meetings (GlobeNewswire)
Dec-04-24 04:15PM	Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study (GlobeNewswire)
Dec-02-24 04:05PM	Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms (GlobeNewswire)
Nov-13-24 02:21AM	OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ... (GuruFocus.com)
Nov-12-24 04:05PM	Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 (GlobeNewswire)
04:45PM	Loading…
Nov-06-24 04:45PM	Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 (GlobeNewswire)
Oct-16-24 04:15PM	Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles (GlobeNewswire)
Oct-08-24 08:30AM	Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial (GlobeNewswire)
Oct-04-24 06:28AM	OncoCyte Secures Funding Through Private Share Sale (TipRanks)
Oct-02-24 06:41PM	Oncocyte Signs Leading Transplant Centers in US and Germany (GlobeNewswire)
06:35PM	Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Aug-20-24 09:00AM	PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology (GlobeNewswire)
Aug-12-24 04:10PM	Oncocyte's VitaGraft Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study (GlobeNewswire) -5.13%
Aug-08-24 04:05PM	Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results (GlobeNewswire)
Aug-05-24 04:05PM	Oncocyte Announces August Investor Conferences Participation (GlobeNewswire) +6.27%
04:05PM	Loading…
Aug-01-24 04:05PM	Oncocyte to Announce Second Quarter 2024 Financial Results on August 8 (GlobeNewswire) -5.14%
Jul-11-24 08:00AM	MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in 'Take Advantage of the Moment' Episode (GlobeNewswire)
Jun-24-24 12:41PM	Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move (GlobeNewswire) -6.36%
Jun-17-24 04:05PM	Oncocyte Appoints Andrea James as Chief Financial Officer (GlobeNewswire)
Jun-05-24 07:00AM	OncoCyte's Innovative Approach: Potential in Precision Diagnostics (News Direct)
Jun-03-24 02:13PM	Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study (GlobeNewswire)
May-30-24 04:47PM	Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine (GlobeNewswire)
May-15-24 08:55PM	OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	Oncocyte Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-13-24 08:00AM	Oncocyte to Announce First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 09:19AM	PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace (GlobeNewswire)
Apr-12-24 10:52AM	OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -8.60%
06:00AM	Oncocyte Reports Full Year 2023 Financial Results (GlobeNewswire)
Apr-11-24 09:46PM	Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
05:30PM	Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay (GlobeNewswire)
04:05PM	Loading…
Apr-09-24 04:05PM	Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Jan-16-24 08:00AM	Oncocyte to Present at the Sequire Investor Summit in Puerto Rico (GlobeNewswire)
Dec-06-23 08:00AM	Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays (GlobeNewswire)
Nov-09-23 08:27AM	OncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the Horizon (GuruFocus.com) +29.71%
07:00AM	Oncocyte Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 08:30AM	Oncocyte to Announce Third Quarter 2023 Financial Results (GlobeNewswire) +8.09%
Sep-18-23 08:00AM	Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier (ACCESSWIRE) +5.49%
Sep-06-23 08:00AM	Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE)
Aug-28-23 08:30AM	Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage (ACCESSWIRE)
Aug-10-23 07:00AM	Oncocyte Reports Second Quarter 2023 Financial Results (ACCESSWIRE)
Aug-09-23 08:00AM	Oncocyte Regains Compliance With Nasdaq Listing Requirements (ACCESSWIRE)
Aug-08-23 08:30AM	Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference (ACCESSWIRE) -5.29%
Aug-03-23 08:00AM	Oncocyte To Announce Second Quarter 2023 Financial Results (ACCESSWIRE)
Jul-25-23 09:08AM	VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients (GlobeNewswire)
Jul-24-23 01:35PM	Oncocyte Announces 1-For-20 Reverse Stock Split (GlobeNewswire) -9.57%
Jun-27-23 08:30AM	Oncocyte Begins Manufacturing Transplant Blood Test (GlobeNewswire)
Jun-01-23 04:15PM	Oncocyte Corporation to Present at the LD Micro Invitational XIII (Newsfile) +6.55%
May-11-23 08:00AM	Oncocyte Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 04:59PM	Oncocyte To Announce First Quarter 2023 Financial Results (GlobeNewswire) +9.86%
Apr-18-23 08:45AM	Oncocyte Presents New Data at AACR (GlobeNewswire)
Apr-12-23 04:15PM	Oncocyte Announces Reduction in Force (GlobeNewswire) -5.08%
Apr-07-23 08:24AM	Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer (GlobeNewswire)
Apr-03-23 08:00AM	Oncocyte Pricing of $13.86 Million Public Offering of Common Stock (GlobeNewswire) -10.41%
Mar-31-23 05:00PM	Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K (GlobeNewswire) +26.57%
Mar-29-23 04:01PM	Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call (GlobeNewswire) +5.52% -8.50%
Mar-15-23 04:01PM	Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -20.00% +51.50%
Mar-02-23 09:00AM	Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer (GlobeNewswire)
Feb-22-23 08:00AM	Oncocyte Completes Razor Genomics Transaction (GlobeNewswire)
Dec-16-22 08:19AM	Oncocyte cuts 40% of staff (MarketWatch) -21.95%
08:00AM	Oncocyte Announces Initiatives to Focus Corporate Strategy (GlobeNewswire)
Nov-30-22 06:05PM	Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors (GlobeNewswire)
06:00PM	Oncocyte Announces Executive Leadership Changes (GlobeNewswire)
Nov-10-22 04:30PM	Oncocyte Reports Third Quarter 2022 Financial Results (GlobeNewswire) -21.72%
Oct-27-22 04:01PM	Oncocyte to Announce Third Quarter 2022 Financial Results (GlobeNewswire) -13.50%
Oct-06-22 08:00AM	DetermaIO Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer (GlobeNewswire)
Sep-07-22 08:00AM	Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS (GlobeNewswire)
Aug-31-22 04:01PM	Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference (GlobeNewswire)
Aug-30-22 04:27PM	Oncocyte Announces Five-Year VA Contract for DetermaRx (GlobeNewswire) -6.93%
Aug-24-22 08:00AM	Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer (GlobeNewswire)
Aug-10-22 04:05PM	Oncocyte Reports Second Quarter 2022 Financial Results (GlobeNewswire) +10.57%
Aug-03-22 04:01PM	Oncocyte to Participate at Upcoming Investor Conferences (GlobeNewswire) +13.60%
Aug-01-22 11:33AM	The past year for OncoCyte (NASDAQ:OCX) investors has not been profitable (Simply Wall St.)
05:00AM	Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022 (GlobeNewswire)
Jul-27-22 04:01PM	Oncocyte to Announce Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-13-22 08:00AM	Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business (GlobeNewswire) +5.75%
Jul-06-22 08:00AM	Oncocyte Presents DetermaIO Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022 (GlobeNewswire)
Jun-22-22 08:00AM	Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice (GlobeNewswire)
Jun-15-22 07:15AM	How Much Of OncoCyte Corporation (NASDAQ:OCX) Do Insiders Own? (Simply Wall St.)
May-26-22 05:00PM	Oncocyte Presents DetermaIO Data at ASCO 2022 Supporting the Tests Potential to Expand the Clinical Use of Immunotherapy (GlobeNewswire)
May-11-22 04:05PM	Oncocyte Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-05-22 08:00AM	Oncocyte Completes Validation of TheraSure Transplant Monitor Test (GlobeNewswire)
Apr-28-22 04:01PM	Oncocyte to Announce First Quarter 2022 Financial Results (GlobeNewswire)
Apr-27-22 04:30PM	Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO (GlobeNewswire)
Apr-22-22 09:26AM	A number of insiders bought OncoCyte Corporation (NASDAQ:OCX) stock last year, which is great news for shareholders (Simply Wall St.)
Apr-13-22 10:01PM	Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants (GlobeNewswire)
05:12PM	Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
05:10PM	Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock (GlobeNewswire)
Apr-11-22 08:00AM	Oncocyte Presents Confirmatory Data for DetermaIO at the American Association for Cancer Research Annual Meeting 2022 (GlobeNewswire)
Mar-28-22 08:00AM	Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022 (GlobeNewswire)
Mar-10-22 04:05PM	Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +7.69% -7.86%
Mar-01-22 04:05PM	Oncocyte to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday March 10 (GlobeNewswire)
Feb-21-22 07:26AM	Shareholders in OncoCyte (NASDAQ:OCX) have lost 78%, as stock drops 12% this past week (Simply Wall St.)
Feb-10-22 08:00AM	Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire)
Jan-18-22 04:05PM	Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology (GlobeNewswire) +15.87% -24.20%
Jan-06-22 09:43AM	What Type Of Shareholders Make Up OncoCyte Corporation's (NASDAQ:OCX) Share Registry? (Simply Wall St.)
Jan-04-22 08:00AM	Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer (GlobeNewswire)
Dec-09-21 06:00PM	Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocytes DetermaIO Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer (GlobeNewswire) -9.81% -6.28%
Dec-08-21 08:00AM	Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx in China (GlobeNewswire) +10.42%
Dec-06-21 08:00AM	Oncocyte Corporation Hosting Business Update Call (GlobeNewswire)
Dec-02-21 08:00AM	Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021 (GlobeNewswire)

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
James Andrea S.	Chief Financial Officer	Dec 05 '24	Buy	2.29	20,000	45,800	53,670	Dec 09 08:00 AM
James Andrea S.	Chief Financial Officer	Oct 02 '24	Buy	2.97	33,670	100,000	33,670	Oct 04 07:40 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Oct 02 '24	Buy	2.95	1,315,339	3,877,619	6,244,405	Oct 04 07:00 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 11 '24	Buy	2.92	2,420,000	7,057,688	4,929,066	Apr 15 07:21 PM
Riggs Josh	CEO and President	Apr 11 '24	Buy	2.95	3,390	10,000	3,505	Apr 15 06:04 AM
Arno Andrew	Director	Apr 11 '24	Buy	2.95	33,898	99,999	69,054	Apr 15 06:02 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCX

Oncocyte Corporation

Upgrade your FINVIZ experience